Sohail Rao

Sohail Rao


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ZIZafar Iqbal
Zafar Iqbal
AAAbdulkareem Abdulghani Algarni
Abdulkareem Abdulghani Algarni
YTYaqob Taleb
Yaqob Taleb
SASultan Alqahtani
Sultan Alqahtani
MSMuhammad Farooq Sabar
Muhammad Farooq Sabar
SRSohail Rao
Sohail Rao
Background/Objectives: Blast-crisis chronic myeloid leukemia (BC-CML) represents a genomically unstable, therapeutically refractory phase driven by clonal evolution beyond BCR::ABL1 dependence. Clinical outcomes remain poor, with median survival under one year. Mutation-level analyses inadequately resolve biological heterogeneity or inform rational patient-specific therapy. We therefore implemented a mutational process–anchored framework integrating genomics, machine learning (ML), and artificial intelligence (AI)–guided drug prioritization at single-patient resolution. Methods: Whole-exome sequencing, COSMIC mutational signature deconvolution, unsupervised ML clustering, and AI-guided pharmacogenomic prioritization were applied to 224 patients with CML (190 chronic phase, 15 accelerated phase, 19 blast crisis) and 19 healthy controls. Results: Mutation burden increased significantly with disease progression, and blast crisis exhibited complex co-mutation architectures involving TP53, BRCA2, IDH1/2, DNMT3A, JAK2, and CSF3R. While gene-level patterns were heterogeneous, dominant mutational processes converged across cases. COSMIC signature extraction stratified BC-CML into three biologically coherent clusters: homologous recombination deficiency/genomic instability (Signatures 3/5), epigenetic–metabolic dysregulation (Signatures 1/2), and oxidative stress–associated cytokine signaling mutagenesis (Signatures 13/18). These process-defined states mechanistically link DNA repair failure, chromatin remodeling, and inflammatory signaling to blast transformation. Integration with an AI-guided pharmacogenomic framework translated signature biology into rational, cluster-specific therapeutic prioritization, including PARP inhibition, IDH targeting, CDK4/6 blockade, JAK pathway inhibition, and redox-modulating strategies. Dominant signature resolution reduced multidrug ambiguity and supported single-patient therapeutic parsimony. External concordance assessment across independent pharmacogenomic datasets supported predicted vulnerabilities. Conclusions: This study establishes a mechanistically interpretable, process-anchored precision oncology framework for BC-CML linking genomic architecture to actionable therapeutic decision-making warranting clinical validation. The approach can further be implemented for AL-AI-prioritized precision treatment of other relapsed, refractory and metastatic cancers.